La-z-boy Incorporated · NYSE:LZB
La-z-boy — Q4 2025 Earnings Presentation
18 slides from La-z-boy's earnings presentation, Jun 18, 2025
Slide 1: Investor Presentation FY25 Q4
Investor Presentation FY25 Q4 June 2025
Slide 2: Disclaimer
Disclaimer CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS: Certain information contained in this presentation constitutes forward-looking statements under applicable securities laws. Any statements that are contained in this presentation that are not statements of historical fact may be deemed
Slide 3: Diversified Global Business Model
Diversified Global Business Model Focus on Defensive, Stable, High Margin Segments Int’l Medical Canadian Medical Plant Propagation Adult Recreational Science & Innovation International medical revenue #1 Canadian Medical share Net revenue increased 32% in Ability to deliver products that Delivering
Slide 4: Leading Global Cannabis Platform
Leading Global Cannabis Platform • Global medical cannabis net revenue(1) reached $67.8m in Q4, up 48% • Supplied from highly efficient, high quality Canadian EU and TGA GMP compared to the prior year period. manufacturing facilities – a clear competitive advantage in the highly regulated medical ma
Slide 5: Leadership in Key Global Cannabis Markets
Leadership in Key Global Cannabis Markets UNITED KINGDOM: ~68m population POLAND: ~40m population • Strong market position through relationships with key distributors and • Aurora consistently maintains top 3 market share by volume supply of Channel Islands; a high-growth market • High barriers to e
Slide 6: European Medical Leadership
European Medical Leadership Aurora is a leader in the German, Polish and UK markets due to a consistent supply of high-quality and innovative EU GMP cannabis products. Aurora Product Range Consistent Revenue Stream and Margin Leader PEDANIOS 31/1COS-CA • Aurora Europe posted a strong Q4 in FY25, mad
Slide 7: Australia & New Zealand Market Leadership
Australia & New Zealand Market Leadership Following the acquisition of MedReleaf Australia, the # 2 player in the market, Aurora continues to expand its medical product portfolio, to meet the growing needs of the patients in Australia and New Zealand. Consistent Market Share and Margin Leader • #2 M
Slide 8: FY25 Product Launches: Australia & New Zealand
FY25 Product Launches: Australia & New Zealand During FY25, 31 new SKUs were launched in Australia and New Zealand, covering a wide range of formats and catering to multiple patient segments. In Q4, we launched 3 high potency pastilles under the Aurora Brand – providing Australian patients with a la
Slide 9: Canadian Medical Leadership
Canadian Medical Leadership Aurora is leading the market with four owned brands and a wide variety of marketplace offerings. Consistent Revenue Stream and Margin Leader • #1 Canadian Medical Share by revenue; ~1% net revenue(1) growth year over year Value Core • Direct-to-patient controlled distribu
Slide 10: Latest Canadian Medical Releases
Latest Canadian Medical Releases Dried Flower Lotions & Topicals Oils & Capsules Edibles & Beverages Vapes & Concentrates • WMMC Kootna Kush • Arctic Heat Cream • Coming Soon: • Being CBD Golden Guava • Aurora Medical Solara 510 • WMMC Pomelo Fresco • Arctic Heat Relief stick o Medreleaf Equiberry G
Slide 11: A Compelling Portfolio of Adult Recreational Brands
A Compelling Portfolio of Adult Recreational Brands Core Alternative Premium Super Premium Maximum Flavour, Maximum Potency, High-THC edibles for the Proprietary genetics with unique aromas Exceptional true-to-cultivar, craft offerings. Brand Promise Maximum Value modern-day consumer in a range of s
Slide 12: Sales and Marketing Support
Sales and Marketing Support Ongoing national campaign focused on maximizing brand and product Innovation will be communicated to retailers via national e-mail and in- awareness, further enhancing purchase consideration for Tasty's Vapes. store pitches. They will be supported by a full suite of digit
Slide 13: Plant Propagation Overview
Plant Propagation Overview Aurora holds a controlling interest in Bevo Farms, an industry leader in plant propagation and one of the largest suppliers of propagated vegetables and ornamental plants in North America. • Bevo contributed strong revenues of ~$13.8 million in Q4 up 32% compared to the pr
Slide 14: Science & Innovation Program
Science & Innovation Program A state-of-the-art breeding facility in Vancouver Island’s Comox Valley: • Built specifically to develop the next big cultivars: high potency, with excellent bud structure and density, highly aromatic and expressing unique terpene profiles sought by patients and consumer
Slide 15: Key Takeaways
Key Takeaways Opening the Achievement of Robust and Enabled by World to Financial $ Differentiated Science Cannabis Milestones Balance Sheet Achieved positive free cash flow1 of Largest global medical cannabis Completed final repayment of CAD Leading cannabis plant genetic work $2.5 million
Slide 16: Senior Management Team
Senior Management Team Miguel Martin Executive Chairman & CEO Miguel’s career spans nearly 30 years in consumer- packaged goods, covering various regulated categories and fast-moving markets. Miguel is the former CEO & President of Reliva. Simona King Nathalie Clark Alex Miller Chief Financial Offic
Slide 17: Board of Directors
Board of Directors Miguel Martin Executive Chairman & CEO Miguel’s career spans nearly 30 years in consumer- packaged goods, covering various regulated categories and fast-moving markets. Miguel is the former CEO & President of Reliva. Norma Beauchamp Theresa Firestone Ronald Funk Director Director
Slide 18: Investor Presentation
Investor Presentation Email: aurora@icrinc.com Website: auroramj.com/investors